PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
March 1, 2024Cancer MedicineOpen Access

The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJindřich KopeckýMPMarek PásekRLRadek Lakomý

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kopecký et al. (2024) studied this question.

synapsesocial.com/papers/68e76333b6db6435876d8f86https://doi.org/10.1002/cam4.6982
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center’s decade of experience2024 · 10 citations
  2. 2Comparative effectiveness of different interventions in metastatic melanoma: A network meta-analysis.2026
  3. 3Prospective real-world evidence for the use of immune-checkpoint inhibitors and BRAF-targeted therapy in advanced melanoma from a large Canadian cohort.2024
  4. 4Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States2024 · 1 citations
  5. 5Adjuvant Targeted Therapy Versus Anti-PD-1 Immunotherapy in BRAF-Mutated Stage III Melanoma: a Real-World Data2024